研究发现,新的血液测试显示,有望改善对转移性乳腺癌的治疗和控制。 New blood tests show promise in improving treatment and control of metastatic breast cancer, study finds.

新的研究表明,“液体活性细胞”、检测肿瘤细胞和DNA的血液测试,可以改善对转移性乳腺癌的治疗,将肿瘤控制在一年以上。 New research shows that "liquid biopsies," blood tests detecting tumor cells and DNA, can improve treatment of metastatic breast cancer, keeping tumors under control for over a year. 根据这些测试改变治疗方法的病人控制肿瘤的概率是他们的两倍。 Patients who changed treatment based on these tests were twice as likely to control their tumors. 测试可比成像提前九个月检测突变情况,从而有可能进行更早、更有效的治疗。 The tests can detect mutations up to nine months earlier than imaging, potentially allowing for earlier, more effective treatments. 该研究使用了AstraZeneca的实验药物卡梅斯特兰特,该药物将癌症发病或死亡的风险减半,尽管尚未获得林业发展局的核准。 The study used AstraZeneca's experimental drug, camizestrant, which cut the risk of cancer progression or death by half, though it is not yet FDA-approved.